On April 22, 2026, the National Medical Products Administration (NMPA) issued Announcement No. 40 of 2026, deciding to ...

Depending on one’s perspective, the anti-inflammatory colchicine is either an unsung and underprescribed drug for patients with cardiovascular disease, or it’s an agent with limited clinical benefit ...

(Boston)—Gout is the most common form of inflammatory arthritis, with worldwide prevalence of approximately four%. The accumulation of monosodium urate crystals in gout leads to the clinical ...

Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price. Well intentioned, but costly and potentially problematic. That's how ...

Cheap drug commonly prescribed for gout could slash heart attack risk - Colchicine is a first-line treatment for gout on the NHS ...